Blood pressure decrease with ingestion of a soya product (kinako) or fish oil in women with the metabolic syndrome: role of adiponectin and nitric oxide

Andréa Name Colado Simão1, Marcell Alysson Batisti Lozovoy2, Larissa Danielle Bahls1, Helena Kaminami Morimoto1, Tathiana Name Colado Simão3, Tiemi Matsuo4 and Isaias Dichi5*

1Department of Pathology, Clinical Analysis and Toxicology, University of Londrina, Londrina, Paraná, Brazil
2Department of Clinical Analysis, University of North Paraná (UNOPAR), Londrina, Paraná, Brazil
3Department of Nutrition, University of North Paraná (UNOPAR), Londrina, Paraná, Brazil
4Department of Statistics, University of Londrina, Londrina, Paraná, Brazil
5Department of Internal Medicine, Rua Robert Koch no. 60, Bairro Cervejaria, University of Londrina, Londrina, Paraná, CEP 86038-440, Brazil

(Submitted 13 May 2011 – Final revision received 23 November 2011 – Accepted 23 November 2011 – First published online 8 February 2012)

Abstract
The aim of the present study was to verify the effects of fish oil and a soya-based product on inflammatory markers and endothelial function measured by NO in women with the metabolic syndrome (MetS). A total of sixty-five women (mean age: 47.9 (SD 9.98) years) were studied in a 90-d parallel, randomised design. A control group maintained their usual diet; the second group received 29 g/d of soyabean (kinako); the third group received 3 g/d of fish oil \( n-3 \) fatty acids; and the fourth group received fish oil (3 g/d) and kinako (29 g/d). Anthropometric, blood pressure (BP), inflammatory markers, anti-inflammatory marker (adiponectin) and NO concentrations were evaluated. In relation to the baseline values, the group that received fish oil and kinako concomitantly presented a statistically significant decrease in systolic BP \( (P<0.05) \), whereas there was a significant decrease in diastolic BP \( (P<0.05) \) in the control group, kinako group \( (P<0.01) \) and fish oil group \( (P<0.01) \) after 90 d. There was a significant increase in adiponectin \( (P<0.01) \) and NO values \( (P<0.05) \) after 90 d in the kinako and fish oil groups. Differences between treatment groups verified a significant decrease \( (P<0.05) \) in DBP in the kinako group after 90 d when compared to the results obtained from the fish oil and kinako groups. In conclusion, the findings of increased serum adiponectin and NO metabolite levels after 90 d, both in the fish oil and soya groups, reinforce the importance of the influence of adiponectin and NO levels on BP decrease in patients with the MetS.

Key words: Metabolic syndrome: Soya: \( n-3 \) Fatty acids: Adiponectin: Nitric oxide

The metabolic syndrome (MetS) comprises pathological conditions that include insulin resistance, arterial hypertension, visceral adiposity and dyslipidaemia, which favour the development of CVD(1). Existing evidence suggests that the MetS is rising in both developed(2) and developing countries, such as Brazil(3).

Currently, many factors are thought to be involved in the beneficial cardiovascular effects of fish oil \( n-3 \) fatty acids(4), such as alteration of plasma lipid profile by decreasing plasma TAG content; reduced agonist-induced activation of NF-\( \kappa \)B and increased PPAR\( \gamma \); decreases in inflammatory markers and in vascular cell adhesion molecules; and decreased synthesis of inflammatory PG and leukotrienes. On the other hand, soya-based products and their components(5) are involved in improving blood lipid profiles, and particularly in decreasing total and LDL-cholesterol; besides, soya products can also reduce blood glucose levels in postmenopausal women with type 2 diabetes mellitus and the MetS. Fish or fish oil consumption has been recommended as part of disease management to prevent death due to CHD, both as a preventive measure and after a coronary event, largely due to its properties that prevent fatal CHD and sudden cardiac death(5). Dietary soya has also been recommended for its potential role in CVD, although the recommendation has changed from soya protein or isoflavones to soya products because of their high content of polyunsaturated fats, fibre, vitamins and minerals and low content of saturated fat(5).

Elevated blood pressure (BP) results from environmental factors, genetic factors and interactions among these factors.

Abbreviations: BP, blood pressure; DBP, diastolic blood pressure; eNOS, endothelial NO synthase; MetS, metabolic syndrome; SBP, systolic blood pressure; WC, waist circumference.

* Corresponding author: I. Dichi, fax +55 43 5571 2328, email dichi@sercomcom.br
Among the environmental factors that affect BP, dietary factors have a prominent and probably predominant role\(^6\). Several clinical trials and meta-analysis have identified nutritional strategies using soya-based products\(^7\) or fish oil\(^10\) as non-invasive approaches to managing and reducing the risk of elevated BP.

Fish oil \(n-3\) fatty acids and soya-based products may exert some of their beneficial actions through changes in pro-inflammatory and anti-inflammatory (adiponectin) adipocytokines, and endothelial function\(^10\)\(^–\)\(^14\). In a recent report, our group showed an increase in NO levels and a decrease in diastolic BP (DBP) in patients with the MetS receiving a soya-based product (kinako)\(^15\).

To the best of our knowledge, the present study is the first to report the effects of fish oil and a soya-based product, used in isolation and concomitantly, on inflammatory markers and endothelial function measured by NO in women with the MetS. Our hypothesis is that a decrease in SBP and/or DBP with soya or fish oil ingestion could be partially explained by an increase in adiponectin and NO levels and that the association of the supplements would lead to better results than their isolated use.

Therefore, the aim of the present study was to verify the effects of fish oil and soyabean intake on inflammatory markers, endothelial function and BP.

### Subjects and methods

A total of 100 \((n=100)\) women with the MetS from ambulatory patients of the University Hospital of Londrina, Parana, Brazil were contacted by telephone, and thirty-one were considered ineligible (Fig. 1). The remaining sixty-nine \((n=69)\) women were randomised and began to participate in the study (Fig. 1). No subject was paid to participate in the study. Their motivation was related to the intake of a non-pharmacological therapy that was practically without side effects. The mean age of the patients was 47.9 (SD 9.98) years. The distribution of postmenopausal women \((n=40)\) between the groups was similar. The control and fish oil groups included ten postmenopausal women, the kinako group included eleven, and the combined fish oil and kinako group included nine. The exclusion criteria were thyroid, renal, hepatic, gastrointestinal or oncological diseases and utilisation of lipid-lowering drugs, oestrogen replacement therapy, drugs for hyperglycaemia, and fish oil or soya supplements. Patients who were taking antihypertensive drugs were not excluded and were allowed to continue taking the same dose of the drugs. None of the subjects followed a specific diet before the study began.

The patients were instructed not to change their usual diets, alcohol intake, level of physical activity or other lifestyle factors throughout the intervention period. This study was conducted according to the guidelines laid down in the Declaration of Helsinki and all procedures involving human subjects/patients were approved by the Ethical Committee of the University of Londrina, Parana, Brazil (study protocol CEP 298/05). Written informed consent was obtained from all subjects/patients.

### Study design

Before beginning the study, the patients were followed up on a regular basis. Patients were randomly assigned to one of four groups after stratification by age and BMI. The first group (control group, \(n=15\)) was only directed to maintain its usual diet; the second group (kinako group, \(n=15\)) received 29 g/d of kinako (toasted ground soya bean, with 50 mg of isoflavones and 12.95 g/d of soya protein) at lunch and dinner; the third group (fish oil group, \(n=19\)) received 3 g/d of fish oil \(n-3\) fatty acids (ten capsules); and the fourth group (fish oil and kinako group, \(n=16\)) received 3 g/d of fish oil \(n-3\) fatty acids and 29 g/d of kinako. Each fish oil capsule contained 180 mg of EPA and 120 mg of DHA. The capsules were given at breakfast, lunch and dinner. The subjects were recommended to refrain from resting after meals to avoid unpleasant effects. All the groups were evaluated at the beginning of the study and after 90 d. Interviews were conducted to ensure that there was no change in lifestyle factors throughout the study. Kinako was provided by Good Soy, Uberaba, Minas Gerais, Brazil, and its quality was certified by the Brazilian Farming Research Company (Embrapa-Soja). The nutrient composition of 29 g of kinako was as follows: 539-53 kJ (128-95 kcal), 12.95 g protein, 6.35 g carbohydrate, 5.75 g lipids, 3.95 g fibre, 83-25 mg Ca, 2.75 mg Fe, 3.5 \(\mu\)g vitamin A, 0.23 mg vitamin B\(_1\), 0.075 mg vitamin B\(_2\), 0.61 mg niacin and 50 mg isoflavones.

Anthropometric measurements and biochemical parameters were assessed at the beginning of the study and after 90 d.
The MetS was defined following the Adult Treatment Panel III criteria, when three of the following five characteristics were confirmed: (1) abdominal obesity: waist circumference (WC) $\geq 88$ cm; (2) hypertriglyceridaemia $\geq 1.695$ mmol/l; (3) low levels of HDL-cholesterol $\leq 1.295$ mmol/l; (4) high BP: $\geq 130/85$ mmHg; (5) high fasting glucose $\geq 6.1$ mmol/l.

Steps taken to optimise compliance

Various measures were taken to optimise and assess patient compliance. Before each trial began, it was ensured that the patients understood that they could be allocated to any group. Boxes of fish oil capsules were handed out at the initial interview and at the two later visits. The subjects were asked to return the boxes at each visit so that the number of capsules taken could be estimated by questioning the patients and counting the remaining capsules. Kinako compliance was measured by questioning the patients and counting the kinako packages when patients returned for their clinical and nutritional evaluation.

Anthropometric and blood pressure measurements

Body weight was measured to the nearest 0.1 kg by using an electronic scale, with individuals wearing light clothing and no shoes; all patients were weighed in the morning. Height was measured to the nearest 0.1 cm using a stadiometer. BMI was calculated as weight (kg) divided by height (m) squared. WC was measured with a soft tape on standing subjects midway between the lowest rib and the iliac crest. Following these, three BP measurements, taken with a minute’s interval between them after the subject had been seated, were recorded. The mean of these measurements was used in the analysis.

The subjects had been seated for at least 5 min in a chair with back support and with feet on the floor, and smoking, alcohol and exercise were avoided for at least 30 min before the measurement. BP was measured by only one person who was trained and retrained properly. Recommendations of the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure were followed.

Inflammatory markers and cytokine measurements

Serum high-sensitivity C-reactive protein was measured using a nephelometric assay (Dade-Behring). Additionally, serum TNF-$\alpha$, IL-6 and adiponectin were measured by a sandwich ELISA using a commercial immunoassay (R&D System).

Nitric oxide

Serum NO metabolite levels were assessed by nitrite ($\text{NO}_2^-$) and nitrate ($\text{NO}_3^-$) concentration according to the Griess reaction, supplemented by the reduction of nitrate to nitrite with Cd.

Statistical analysis

The distribution of the number of medications was analysed by a $\chi^2$ test. The Wilcoxon matched pairs test was performed to verify changes from baseline (intra-group changes). ANOVA was performed to compare differences between ages. The Kruskal–Wallis with post hoc Dunn’s test was performed to verify differences between BMI and to compare differences across treatment groups (inter-group changes). Data are presented as the means and standard deviations or medians and 25th–75th percentiles. Significance was set at $P<0.05$.

Results

Overall, four patients withdrew from the study: two patients in the kinako group and two patients in the group that received fish oil and kinako. All subjects ($n=65$) who completed the study reached a level of compliance above 90% of fish oil and kinako ingestion.

In general, the participants had no major complaints, except for the fishy taste and self-limited diarrhoea reported by three

| Table 1. Characteristics of the patients with the metabolic syndrome |
|-------------------|-----------------|-----------------|-----------------|-----------------|
| Parameters        | Control ($n=15$) | Kinako ($n=15$) | Fish oil ($n=19$) | Kinako + fish oil ($n=16$) |
| Age (years)†      | 47.1            | 49.9            | 47.5            | 47.9            |
| SD                | 8.8             | 11.2            | 9.2             | 10.2            |
| BMI (kg/m$^2$)‡   | 35–36           | 37–31           | 32.93           | 34.71           |
| Smoking§          | 0               | 1               | 2               | 1               |
| ACE§              | 8               | 10              | 9               | 7               |
| b Blockers§       | 1               | 2               | 4               | 3               |
| Diuretics§        | 5               | 7               | 5               | 4               |
| CCB§              | 2               | 1               | 1               | 2               |

ACE, angiotensin-converting enzyme; CCB, Ca channel blocker.

* See the Study design section for the diets given to each group. None of the groups differed with respect to the parameters measured.
† ANOVA was performed to compare differences between ages.
‡ The Kruskal–Wallis test was performed to verify differences between subjects’ BMI.
§ Distribution of number of medications was analysed by a $\chi^2$ test.
patients in the fish oil groups. According to the self-reports, each subject's lifestyle was unchanged throughout the study. In all groups, subjects did not drink alcohol regularly. There were no differences between groups with respect to age, smoking status, Ca channel blockers, β blockers and diuretics (Table 1). Despite their influence on adiponectin levels, for ethical reasons we could not ask the patients to stop using antihypertensive (angiotensin-converting enzyme inhibitors) medication during the study, but there was no statistically significant difference between groups when they were compared. There were no significant differences in any laboratory parameter studied at baseline.

In relation to baseline values, WC showed a statistically significant decrease in the kinako group (P<0·05), whereas WHR increased significantly (P<0·05) after 90 d in the group that received both fish oil and kinako. The group that received fish oil and kinako concomitantly showed a statistically significant decrease in SBP (P<0·05), whereas there was a significant decrease in DBP in the control group (P<0·05), kinako group (P<0·01) and fish oil group (P<0·01) after 90 d in relation to the baseline values (Table 2).

Differences across treatment groups showed a statistically significant decrease (P<0·05) in DBP in the kinako group after 90 d when compared to the results obtained from the combined fish oil and kinako group (Table 2).

In relation to inflammatory markers, there were significant increases in IL-6 values in the kinako group (P<0·05) and in adiponectin values after 90 d in the kinako (P<0·01) and fish oil (P<0·05) groups in relation to the baseline values. The C-reactive protein and TNF-α values did not differ significantly in any group (Table 3).

Serum NO metabolite levels showed a significant increase (P<0·05) in the kinako and fish oil groups after 90 d when compared to the baseline values (Table 3).

Differences between treatment groups showed a statistically significant increase (P<0·05) in IL-6 in the kinako group compared with data from the combined fish oil and kinako group (Table 3).

**Discussion**

To our knowledge, this is the first study to report a simultaneous increase in adiponectin and NO levels in patients with the MetS consuming a soya-based product or fish oil. Conceivably, these data can explain, at least partially, the BP decrease found in the present study with kinako or fish oil ingestion.

**Effects of fish oil and kinako on inflammatory markers and adiponectin**

In the present investigation, as in most supplementation studies with n-3 fatty acids or soya (22,23), we found no effect on C-reactive protein or TNF-α, but unexpectedly there was an increase in IL-6 levels with kinako ingestion. The current understanding of the role of IL-6 in the context of obesity is ambivalent. IL-6 can be viewed as a proinflammatory cytokine which induces C-reactive protein secretion, but may also be regarded as an anti-inflammatory cytokine as it induces the synthesis of IL-1 receptor antagonist and the release of soluble TNF receptor, leading to reduced activity of proinflammatory cytokines (24). There is also growing evidence that IL-6 has a

<table>
<thead>
<tr>
<th>Table 2. Anthropometric and blood pressure measurements in patients with the metabolic syndrome at baseline, and after 90 d of intervention†‡</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Group§</strong></td>
</tr>
<tr>
<td><strong>(Medians and 25th–75th percentiles)</strong></td>
</tr>
<tr>
<td><strong>Body weight (kg)</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>WC (cm)</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>SBP (mmHg)</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>DBP (mmHg)</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

WC, waist circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure.

Mean value was significantly different from that at baseline: * P<0·05, ** P<0·01.
† Percentage change from baseline was significantly different from that for the kinako + fish oil group (P<0·05).
‡ The Wilcoxon matched pairs test was performed to verify changes from baseline (intra-group changes). The Kruskal–Wallis with post hoc Dunn’s test was performed to compare differences across treatment groups (inter-group changes). Significance was set at P<0·05.
§ See the Study design section for the diets given to each group.
role in inducing lipolysis and decreasing appetite and weight gain, thus controlling obesity-associated pathologies. In the present study, we found a significant decrease in WC in the kinako group, which favours the latter hypothesis. Soya-based products, due to their high contents of protein and fibre, may have beneficial effects on satiety. They may even produce weight loss with a decrease in fat mass but not muscle mass in overweight and obese subjects. On the other hand, the lack of increase in IL-6 levels in the fish oil group could be explained by a decrease in IL-6 levels that may occur with fish oil ingestion; however, IL-6 levels did not decrease in the fish oil group in the present study.

Similar to data of the present study, some experimental studies have reported beneficial anti-inflammatory effects of soya protein or isoflavone, shown by increasing adiponectin levels. Charles et al. showed an increase in adiponectin levels in healthy, normal-weight, postmenopausal women with high doses of isoflavones (20 g of soya protein with 160 mg of isoflavone).

$n$-3 Fatty acids have been shown to increase adiponectin levels in both experimental and human studies. Itoh et al. reported that EPA (1.8 g/d) increases adiponectin secretion possibly through the improvement of the inflammatory changes in obese adipose tissue in rodent models of obesity and human obese subjects. Lara et al. also verified a trend towards an increase in plasma adiponectin, independent of weight change with 125 g/d of salmon consumption (2.4 g/d $n$-3 fatty acids) in non-obese healthy subjects.

Experimental studies have revealed that the transcription factor PPAR$\gamma$ is perhaps the main mechanism by which $n$-3 fatty acids may increase adiponectin levels. Of note, $n$-3 fatty acids act like the thiazolidinediones, which are PPAR$\gamma$ agonists and are used in the treatment of insulin-resistant and diabetic subjects. However, different from our results, some studies have not found an adiponectin increase with $n$-3 fatty acids supplementation in healthy, overweight to moderately obese subjects, or in patients with type 2 diabetes. There are some concerns about those studies related to using olive oil as placebo. These concerns include the following: olive oil is not an inert compound and has shown beneficial anti-inflammatory effects; the anti-inflammatory low dose of 1.8 g/d $n$-3 fatty acids, as circulating adiponectin, is associated with plasma $n$-3 fatty acids concentration; and these studies analysed small samples.

**Effects of fish oil and kinako on endothelial function**

The present study is in line with others that show an improvement in endothelial function mediated by NO, in healthy postmenopausal women using isoflavone or in postmenopausal women with the MetS using a soya nut diet (30 g/d). Experimental studies indicate that isoflavone supplementation does not improve endothelial function in women with high baseline flow-mediated dilatation values.
but it does lead to significant improvement in postmenopausal women with low baseline flow-mediated dilatation values, an endothelial marker predominantly mediated by \( \text{NO} \). Our data showed low baseline serum \( \text{NO} \) metabolite levels, which may have contributed to the favourable results obtained with kinako.

\( \text{n-3} \) fatty acids have also shown an improvement in endothelial function mediated by \( \text{NO} \) in subjects with hypercholesterolaemia and diabetes mellitus. Collectively, in vitro studies suggest that endothelial-dependent vessel relaxation is due to the enhancement of \( \text{NO} \) release. However, another study in hypertriglycerolaemic subjects did not show an \( \text{NO} \) increase with high doses (7.5 g/d) of \( \text{DHA} \); however, the authors used olive oil as the placebo. Olive oil modulates \( \text{NO} \) biosynthesis and increases \( \text{eNOS} \) expression, and therefore it is not an ideal placebo.

Of note, whereas fish oil action on \( \text{NO} \) may result from increased expression of \( \text{eNOS} \), it can be hypothesised that the relatively higher amount of the \( \text{NO} \) precursor, arginine, in the amino acid profile of soya protein could explain, at least in part, its effects on \( \text{NO} \) concentration. The \( \text{L-arginine/NO} \) pathway plays a critical role in maintaining normal endothelial function by causing vasodilatation.

**Effects of fish oil and kinako on blood pressure**

Although dietary behaviour could have influenced the non-significant decline in SBP and the significant reduction in DBP in the control group, there were no major changes in subjects’ habitual intake as well as in other factors, such as physical activity and also in \( \text{NO} \) and adiponectin levels.

Similar to our findings, soya intake has been shown to have an inverse association with BP both in longitudinal studies and in small-scale clinical trials. However, in contrast to our results, Azadbakht et al. used soya protein or soya nuts (30 g/d) in MetS patients but did not show a significant decrease in BP.

Human studies have also shown that fish oil can lower BP. A meta-regression analysis of randomised trials verified that at doses between 3 and 5.6 g/d, fish oil reduced BP in hypertensive individuals by up to 5-5/3.5 mmHg. Furthermore, \( \text{n-3} \) fatty acids intake is related inversely to BP, including in non-hypertensive persons, in seventeen population-based samples in China, Japan, the UK and the USA.

Because there was no significant increase in adiponectin and \( \text{NO} \) levels in the group that received concomitant kinako and fish oil, decreased SBP in this group may be justified by other pathophysiological mechanisms, other than adiponectin and \( \text{NO} \).

In the present study, although the decrease in DBP in the kinako group could be explained by the concomitant decrease in WC, there was a decrease in SBP in the group that received kinako and fish oil, reinforcing the assumption that the effects of kinako and fish oil on BP are beyond weight loss.

We had also expected a synergistic effect with both supplements in DBP, which has not occurred. Perhaps, the small number of individuals has not allowed this finding.

**Link between the effects of adiponectin, endothelial function and blood pressure**

Numerous epidemiological studies based on different ethnic groups have identified adiponectin deficiency as an independent risk factor for endothelial dysfunction, hypertension, CHD, myocardial infarction and other cardiovascular complications. On the other hand, decreased bioavailability and/or impaired production of \( \text{NO} \) is considered a major cause of endothelial dysfunction, which is now recognised as one of the earliest changes in atherosclerosis.

In experimental studies, adiponectin has been shown to enhance \( \text{NO} \) production in cultured aortic endothelial cells, to significantly increase \( \text{eNOS} \) (83 %) and reduce inducible \( \text{NO} \) synthase (70 %) in hyperlipidaemic rats and to improve obesity-related hypertension in mice. Adiponectin has anti-inflammatory effects and augments blood flow by enhancing \( \text{NO} \) production and activating \( \text{eNOS} \), and it may act as a modulator of vascular remodelling by suppressing smooth muscle cell migration, which possibly plays a role in the regulation of atherosclerosis. Human studies have also shown that hyperadiponectinaemia is closely linked to endothelial dysfunction in healthy and in hypertensive subjects. Although other mechanisms, aside from \( \text{NO} \), can explain the effects of soya and fish oil on BP improvement, NO has been considered the principal mediator of vasodilatation caused by endothelial cells. NO plays a major role in regulating BP, and its deficient bioactivity is an important component of hypertension. Hypertensive subjects have increased generation of reactive oxygen species, which scavenger NO, thereby reducing \( \text{NO} \) bioavailability.

Thus, it is conceivable that the present findings of adiponectin and \( \text{NO} \) increase may explain, at least in part, the BP decrease with fish oil or kinako ingestion in MetS patients.

Limitations of this study are the small number of subjects and the antihypertensive drugs the patients were taking, such as angiotensin-converting enzyme inhibitors, which may elevate plasma adiponectin levels and \( \beta \) blockers, which may have synergistic antihypertensive action with fish oil. However, statistical analyses between the groups were not significantly different, and the patients’ medication regimens remained unchanged during the intervention period.

In conclusion, the findings of increased serum adiponectin and \( \text{NO} \) metabolite levels after 90 d, both in the fish oil group and the kinako group, reinforce the importance of the influence of adiponectin and \( \text{NO} \) levels on DBP decrease in patients with the MetS. A synergistic beneficial effect was verified with the concomitant use of fish oil and kinako on SBP but was unrelated to changes in adiponectin and...
NO levels. Further investigation is warranted to confirm the results obtained in the present study.

Acknowledgements

The present research was supported by the National Council of Brazilian Research – CNPq. The Good Soy Company supplied the kinako. The authors’ responsibilities were as follows: A. N. C. S. collected the data, designed the study, interpreted the results and wrote the manuscript; M. A. B. L., L. D. B. and T. N. C. S. collected the data and interpreted the results; H. K. M. performed cytokine analysis; T. M. performed the statistical analysis; and I. D. developed the hypothesis tested in the study, designed the study, interpreted the results and wrote the manuscript. None of the authors had a competing financial interest or any other conflict of interest in relation to the present study.

References


